# UB-VV400 in Combination With Rapamycin in Relapsed or Refractory B-cell Malignancies

> **NCT06743503** · PHASE1 · RECRUITING · sponsor: **Nanjing IASO Biotechnology Co., Ltd.** · enrollment: 70 (estimated)

## Conditions studied

- Large B-cell Lymphoma

## Interventions

- **GENETIC:** UB-VV400
- **DRUG:** Rapamycin

## Key facts

- **NCT ID:** NCT06743503
- **Lead sponsor:** Nanjing IASO Biotechnology Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-04-11
- **Primary completion:** 2028-05-21
- **Final completion:** 2030-07-31
- **Target enrollment:** 70 (ESTIMATED)
- **Last updated:** 2025-09-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06743503

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06743503, "UB-VV400 in Combination With Rapamycin in Relapsed or Refractory B-cell Malignancies". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06743503. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*